<DOC>
	<DOCNO>NCT00012584</DOCNO>
	<brief_summary>The purpose NIMH-sponsored pilot study collect information efficacy safety drug treatment child adolescent suffer ADHD anxiety disorder . Specifically , study examine benefit stimulant medication alone combination fluvoxamine , selective serotonin reuptake inhibitor ( SSRI ) antianxiety effect . Young people age 6 17 diagnosed co-occurring disorder may eligible participate .</brief_summary>
	<brief_title>Treatment Youth With ADHD Anxiety</brief_title>
	<detailed_description>Many child adolescent mental disorder United States treat multiple psychotropic medication even though much information well medication work together safe administer together . Many youth ADHD co-occurring ( comorbid ) disorder oppositional-defiant disorder , anxiety disorder , mood disorder . There much interest treatment child adolescent comorbid ADHD anxiety disorder common condition clinical practice . When child anxiety ADHD receive stimulant medication ADHD , anxiety may improve . SSRI medication represent reasonable addition stimulant treatment , consider effective anxiety disorder base controlled trial adult open trial child . However , data control study regard tolerability dose combination stimulant treatment ( include methylphenidate ) SSRIs treatment child comorbid ADHD anxiety disorder . In study , child adolescent evaluate presence ADHD Anxiety Disorder . Approximately 120 child adolescent disorder meet study entry requirement ( otherwise medically healthy ) enrol . Children adolescents stable dose stimulant first treat openly methylphenidate 6 week . Those whose ADHD improve initial treatment period continue study refer support community . Those show improvement ADHD anxiety symptom stay methylphenidate additional 8 week . Those show improvement ADHD anxiety ask enter double-blind phase study . In phase , participant randomize ( assigned chance ) receive either fluvoxamine placebo , combination stimulant/methylphenidate , 8 week . Children adolescents enter study stable dose stimulant move directly Double-Blind phase . Participants assign placebo show improvement anxiety 8 week eligible additional 8 week open treatment methylphenidate/stimulant fluvoxamine combination . At end trial , clinical care provide additional month referral outside clinician arrange .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Anxiety , Separation</mesh_term>
	<mesh_term>Fluvoxamine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>ADHD diagnosis DSMIV diagnosis anxiety IQ great 70 residence primary caretaker least 6 month age 617 attend school previous treatment failure intolerance fluvoxamine methylphenidate ( unless currently take another stimulant )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>